RxDoctor Payments Data

Kenneth Cohn, MD

Ophthalmology · South Gate, CANPI 1578581187

Payments from drug & device makers

$4,074in general payments, 2019–2025

Across 235 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Oyster Point Pharma, Inc.$841
  • Novartis$553
  • Bausch & Lomb Americas Inc.$315
  • Sun Pharmaceutical Industries Inc.$251
  • Alcon$183
  • plus $879 from 12 others

What the payments were for

  • Food & beverage$4,03599%
  • Education$160%
  • Entertainment$231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,074 in reported general payments places this provider in the 70th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$180,222
Medicare patients
446
Services billed
2,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine860$497,320
Restasis MultidoseCyclosporine399$275,244
LumiganBimatoprost769$212,522
RestasisCyclosporine173$132,405
XiidraLifitegrast122$95,433
MieboPerfluorohexyloctane/Pf69$52,577
ProlensaBromfenac Sodium125$48,413
Bromfenac Sodium151$48,412
Alphagan PBrimonidine Tartrate149$29,656
Brimonidine Tartrate271$17,112
SimbrinzaBrinzolamide/Brimonidine Tart73$16,051
RocklatanNetarsudil Mesylat/Latanoprost35$14,311
VyzultaLatanoprostene Bunod31$11,793
RhopressaNetarsudil Mesylate35$10,730
TyrvayaVarenicline Tartrate13$10,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis Multidose, Lumigan, Restasis, Alphagan P$1,052$649,8281,490 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$315$159,804222 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$173$52,308152 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$161$25,04170 claims
AlconSimbrinza$183$16,05173 claims
Oyster Point Pharma, Inc.Tyrvaya$841$10,61913 claims
Eyevance Pharmaceuticals LLCFlarex, Tobradex St$42$9,35754 claims
Sun Pharmaceutical Industries Inc.Cequa$251$8,28311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in South Gate

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →